Morningstar Founder Joseph Mansueto Sold About $2.0M as the Data-and-Ratings Story Settled Into a New Range
Joseph Mansueto sold roughly $2.0M of Morningstar stock across two February 2026 sessions, extending a long-running founder liquidity pattern after the stock had already repriced lower from late-2025 highs.
Mansueto Joseph D sold roughly $2.2M of MORN stock across the latest visible selling window. The pattern matters because it happened after the market already had a clear narrative about the company, not while investors were still trying to guess whether the business was working.
What Happened
| Date | Code | Shares | Price | Estimated Value |
|---|---|---|---|---|
| 2026-02-18 | S | 181 | $161.27 | $29,190 |
| 2026-02-18 | S | 1,077 | $159.95 | $172,265 |
| 2026-02-18 | S | 4,201 | $159.11 | $668,431 |
| 2026-02-18 | S | 1,278 | $157.97 | $201,885 |
| 2026-02-17 | S | 513 | $162.69 | $83,460 |
| 2026-02-17 | S | 100 | $162.41 | $16,241 |
| 2026-02-17 | S | 816 | $161.46 | $131,748 |
| 2026-02-17 | S | 4,089 | $160.53 | $656,401 |
The visible cluster added up to about 14,041 shares at an average sale price near $159.89. That is big enough to matter, but it is still much more useful as a pattern read than as a one-day headline.
Why It Matters
Morningstar came into 2026 as a steadier compounder story than a momentum name. In its latest earnings commentary, management kept emphasizing recurring-license resilience, private-markets data expansion, and the durability of the ratings franchise. That context matters because Mansueto was selling after the stock had already moved off its richer late-2025 range, not into a fresh euphoric breakout.
That does not make the selling automatically bearish. It does mean investors should distinguish between healthy founder or executive liquidity and a broader change in alignment. That distinction usually becomes clearer when you compare the cadence, size, and remaining ownership after the window closes.
What Investors Should Not Overstate
This is not a story about management walking away. The better read is that the insider used a visible liquidity window while still leaving substantial ownership on the table. That makes the important question forward-looking: does the pattern repeat, accelerate, or stop?
For readers trying to separate routine selling from a deeper signal, the right comparison set is not just the insider's own history. It is also what peers like MSCI, Moody's, S&P Global, Intercontinental Exchange are doing and how those stocks are trading around their own earnings cycles.
Key Facts
| Insider | Mansueto Joseph D |
|---|---|
| Company | Morningstar, Inc. |
| Recent sell window | 2026-02-17 to 2026-02-18 |
| Estimated value | $2.2M |
| Average sale price | $159.89 |
What to Watch
- MORN valuation reset: whether the stock stabilizes as investors refocus on recurring revenue quality.
- Founder cadence: whether February stays a small liquidity window or turns into a larger 2026 sell program.
- Data-platform execution: whether Morningstar keeps expanding private-markets and workflow revenue fast enough to defend the multiple.
- Ownership signal: whether Mansueto's remaining stake stays large enough that the market treats the sales as maintenance rather than disengagement.
- Peer tape: whether MSCI, Moody's, and S&P Global re-rate differently from Morningstar through the next earnings cycle.
Related Research
Explore all researchIMC-Chicago filed a $275.42B Q4 2025 13F showing 84 new positions, 84 exits, and a book dominated by ETF, index, and derivative-style exposures.
Mar 29, 2026
Q1 2026 13F filings are due May 15, 2026. Track Berkshire, Millennium, Bridgewater and more. See expected filing dates, AI/sector themes, and how to access data the moment it drops.
Mar 31, 2026
Janus Henderson (WhaleScore 75.50) opened 67 new positions while exiting 67 in Q4 2025 — a 13.4% turnover rate signaling active repositioning. New biotech/med-device bets (ISRG, GPCR, PTGX) hint at a healthcare conviction thesis.
Mar 30, 2026
Simplex Trading reported a $177.41B Q4 2025 13F, but the filing reads less like a stock portfolio and more like an options-heavy market-structure book. That distinction is the whole story.
Apr 1, 2026
Scotiabank's $131.31B investment arm entered 114 new positions in Q4 2025 while trimming its dominant internal fund by 25% — one of the most aggressive quarterly reshuffles among top-100 filers.
Mar 30, 2026